TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05468957

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Perclose
Description: Patients will have a PercloseTM device deployed at the arteriotomy. Manual pressure will be held for at least one minute, the beginning of which will correspond to time point zero. Patent hemostasis will be documented after device deployment. Any manual compression needed or per protocol under the disgression of the operator will count towards the time to hemostasis. After hemostasis is achieved in the cath lab the patient will be sent to the post-operative area for monitoring. If any additional bleeding is appreciated, manual compression will again be held. Two hours after the patient has had the PercloseTM device deployed the patient will ambulate. If any new bleeding from the puncture site or under the skin the patient will again lay supine and at least 10 minutes of manual pressure will be held and the an ambulation trial will be attempted at least 30 minutes after the subsequent trial. This will be continued until the patient has no bleeding at the time of ambulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statseal
Description: Patients will have a PercloseTM device deployed at the arteriotomy. A Statseal disc will applied and manual pressure will be held for at least one minute, the beginning of which will correspond to time point zero. Patent hemostasis will be documented after device deployment. Any manual compression needed will count towards the time to hemostasis. After hemostasis is achieved in the cath lab the patient will be sent to the post-operative area for monitoring. If any additional bleeding is appreciated, manual compression will again be held. Two hours after the patient has had the PercloseTM device deployed the patient will ambulate. If any new bleeding from the puncture site or under the skin the patient will again lay supine and at least 10 minutes of manual pressure will be held and the an ambulation trial will be attempted at least 30 minutes after the subsequent trial. This will be continued until the patient has no bleeding at the time of ambulation.
Study: NCT06269211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 240mg IV, Q3W
Study: NCT06340568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT323/DB-1303
Description: intravenous (IV) infusion
Study: NCT05555771

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counterpressure Maneuvers
Description: Movements that can aid in delaying or preventing syncope by recruiting skeletal muscle pumping (via compression of major veins by contracting muscle to eject blood through cardiovascular circuit) and increased sympathetic drive (via sustaining an isometric muscle contraction). In this trial, we will be evaluating three commonly recommended maneuvers of arm tensing, squatting, and leg crossing with arm tensing. Maneuvers should be held for 1-2 minutes, or until symptoms subside.
Study: NCT06383806

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Imagery Rehearsal Therapy (IRT)
Description: The intervention will consist of 7 therapy sessions (once per week for 7 weeks) which will be delivered via videoconference. During the sessions, participants will learn techniques for managing and changing nightmares.
Study: NCT06340568

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: IV bolus or infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: IV infusion
Study: NCT06649383

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: Participant will try virtual reality glasses with tailormade software films to see if it's possible to use them as distraction during awake surgery. We will measure doses of propofol given, level of anxiety, experience of the patient and surgeons satisfaction.
Study: NCT06455787

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: J-Valve Transfemoral (TF) System
Description: Treatment includes using the J-Valve Transfemoral (TF) System, a transcatheter aortic valve replacement system that consists of the J-Valve TF Bioprosthesis and the J-Valve TF Delivery Device and Loading Accessories, during transcatheter aortic valve replacement (TAVR).
Study: NCT05555771

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants will engage in behavioural interventions and avoidance measures that are commonly recommended as a part of usual care for recurrent syncope. This primarily includes recommendations such as staying hydrated, increasing salt intake, avoiding warm temperatures, avoiding standing for long periods of time, and engaging in regular physical activity. Some patients may be prescribed medication (Midodrine, Fludrocortisone), or other assistive interventions (e.g., compression stockings) at the discretion of their physician.
Study: NCT05067673

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: The dry needling will be performed using disposable stainless steel needles (AGU-PUNT needles of size 0.30x50mm or 0.30x60mm depending on the patient) that will be inserted perpendicularly at the point of major hyperalgesia using the Hong technique. The patient will be in the prone position with a pillow placed in the abdominal region. The area will be cleaned with an antiseptic and allowed to air dry for 3 minutes. After this time, the needle will be inserted at the point indicated by the evaluator before reaching the lumbar multifidus by means of echolocation. Once it is assured that it is in the right place, a total of 10 repetitions are performed. The needle will be removed by depositing it in a needle container and a compression will be removed in the treated area until hemostasis is achieved.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo dry needling
Description: Placebo dry needling will be performed with DongBang DB100 Acupuncture Needles which, upon contact with the patient, retract, hiding in the needle handle. The patient will be in the prone position with a pillow in the abdominal region. The area will be cleaned with an antiseptic and allowed to air dry for 3 minutes. At the point indicated by the evaluator, the placebo needle will be placed initially and the introduction of the needle and its location will be simulated with the ultrasound system. 10 repetitions will be performed. The needle will be removed by depositing it in a needle container and a compression will be made in the treated area.
Study: NCT04925180

Intervention type: DRUG
Intervention: Cyproterone Acetate (Androcur, BAY94-8367)
Description: As prescribed by the treating physician
Study: NCT04759339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-920
Description: AG-920 is a sterile, isotonic, non-preserved aqueous solution containing the active ingredient Articaine HCl 8%
Study: NCT05090423

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: balance training alone
Description: The subjects will warm up to stretch the lower extremity for 5 minutes.~The physical therapist will instruct the patient how to use the foot tripod within 5 minutes. And then, giving him or her balance training.~At the first, the patient double legs stand on the ground to throw and catch a ball for 30 seconds, and then one leg stand on the ground to throw and catch a ball for 30 seconds. When finished, the patient can take 1 minutes rest.~Second, the patient will finish the prescribed the task stand on different materials, which included the exercise mat, dynair, bosu and foam roller.
Study: NCT05927701

Intervention type: OTHER
Intervention: Group comparaison
Description: Questionnaires

Intervention type: OTHER
Intervention: Group comparaison
Description: Questionnaires
Study: NCT05642078

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational Vaccine(0.25ml/vial)
Description: Subjects were vaccinated with a dose of low-dose Investigational vaccine on day 0 and day 28 respectively.The site of inoculation for infants aged 6-11 months is the anterolateral thigh, and the site of inoculation for infants aged 12-35 months is the lateral deltoid muscle of the upper arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational Vaccine(0.5ml/vial)
Description: Subjects were vaccinated with a dose of high-dose Investigational vaccine on day 0 and day 28 respectively.The site of inoculation for infants aged 6-11 months is the anterolateral thigh, and the site of inoculation for infants aged 12-35 months is the lateral deltoid muscle of the upper arm.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Active compared Vaccine
Description: Subjects were vaccinated with a dose of active compared vaccine on day 0 and day 28 respectively.The site of inoculation for infants aged 6-11 months is the anterolateral thigh, and the site of inoculation for infants aged 12-35 months is the lateral deltoid muscle of the upper arm.
Study: NCT05090423

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: balance training and neurodynamic intervention for the common peroneal nerve
Description: The physical therapist will give the patient neurodynamic intervention for the common peroneal nerve, which is performed slider the nerve 2 seconds.~The slider technique is repeated 30 seconds for 4 times, each time can be take a rest 1 minutes.~The physical therapist will instruct the patient how to use the foot tripod within 5 minutes. And then, giving him or her balance training.~At the first, the patient double legs stand on the ground to throw and catch a ball for 30 seconds, and then one leg stand on the ground to throw and catch a ball for 30 seconds. When finished, the patient can take 1 minutes rest.~Second, the patient will finish the prescribed the task stand on different materials, which included the exercise mat, dynair, bosu and foam roller.
Study: NCT04816682

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silymarin
Description: Silymarine tablets will be provided irrespective of meal by a registered nurse T.I.D
Study: NCT05387928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KL340399 injection
Description: KL340399 injection is a STING-activating. The strength of KL340399 is 0.2 mg/vial，0.2 mg/vial.
Study: NCT06317441

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: The intervention consists of a probiotic either with a low or high dosage

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: The intervention consists of a probiotic either with a low or high dosage
Study: NCT01549470

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVDNA009-00-VP
Description: Administered as a 4 mg/mL dose by IM injection in the deltoid muscle using the Biojector 2000 needle-free injection management system.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo vaccine
Description: Administered as a 1-mL dose by IM injection in the deltoid muscle using the Biojector 2000 needle-free injection management system.
Study: NCT04851067

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dry Needling and Therapeutic Exercises (DNTEx)
Description: Already included in arm/group descriptions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Therapy and Therapeutic Exercises (MTTEx)
Description: Already included in arm/group descriptions.
Study: NCT04194346

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lung ultrasound
Description: Healthy volunteers will have lung ultrasonography at 15 predetermined sites for a common volume continuum between 5 and 15 cc/kg. For each volume, 3 respiratory cycles will be recorded.
Study: NCT06480786

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation
Description: active spinal cord stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Sham stimulation
Study: NCT06290765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropeginterferon alfa-2b
Description: Ropeginterferon alfa-2b subcutaneously (SC) every two weeks (± 3 days), 250 µg at Day 1, 350 µg at Week 2, and target optimal dose of 500 µg at Week 4.~Phlebotomy should be conducted if confirmed Hct ≥48%, or confirmed Hct ≥45% that is ≥3% higher than baseline Hct value.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Phlebotomy and aspirin
Description: Phlebotomy should be conducted if confirmed Hct ≥48%, or confirmed Hct ≥45% that is ≥3% higher than baseline Hct value, or confirmed Hct ≥45% according to the standard of care for phlebotomy at the institution regardless of the magnitude of the increase compared with the baseline. The same standard or criteria for phlebotomy eligibility should be applied for patients during the study at each study site or institution.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phlebotomy and aspirin
Description: Phlebotomy should be conducted if confirmed Hct ≥48%, or confirmed Hct ≥45% that is ≥3% higher than baseline Hct value, or confirmed Hct ≥45% according to the standard of care for phlebotomy at the institution regardless of the magnitude of the increase compared with the baseline. The same standard or criteria for phlebotomy eligibility should be applied for patients during the study at each study site or institution.
Study: NCT05735353

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-Speed Circuit Resistance Training
Description: three times per week; 45 minutes per session; 12-weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-Speed Multidirectional Yoga
Description: two times per week; 60 minutes per session; 12-weeks
Study: NCT05417906

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Oral prednisolone for 5 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eosinophil-directed care
Description: Oral prednisolone for 5 days if eosinophil count is ≥ 0.300 x 10\^3/µL, or 3 days if eosinophil is \< 0.300 x 10\^3/µL
Study: NCT05358223

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Music
Description: A standard music determined by us for the 1st and 4th groups will be played during the process.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Music
Description: A standard music determined by us for the 1st and 4th groups will be played during the process.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Description: TENS device will be connected to the 3rd and 5th groups during the process and the process will be done in this way.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Description: TENS device will be connected to the 3rd and 5th groups during the process and the process will be done in this way.
Study: NCT05266534

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terlipressin
Description: the efficacy of intramyometrial Terlipressin injection on hemoglobin level and decreasing blood loss in women undergoing open myomectomy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: the efficacy of intramyometrial carbetocin injection on hemoglobin level and decreasing blood loss in women undergoing open myomectomy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: the efficacy of intramyometrial saline injection on hemoglobin level and decreasing blood loss in women undergoing open myomectomy
Study: NCT06567925

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Customized Sleep Coaching
Description: Demonstrate the feasibility of a gradual sleep extension strategy using customized sleep coaching.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Hygiene Training
Description: Sleep hygiene training aimed at increasing sleep efficiency in patients with heart failure with preserved ejection fraction on guideline-directed medical therapy
Study: NCT06401655

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Coaching for People living with Acquired Brain Injury (FC-ABI)
Description: This is an individualized, in-person 10-session financial coaching intervention program. Each session is 45-minutes. In total, participants will be asked to participate in up to 7 hours and 30 minutes of intervention time with a trained Occupational Therapist. Each session will happen 1-1.5 weeks apart and the financial coaching program will last over 3-4 months. The financial coaching sessions will only be offered in-person (at MBIA Winnipeg location, in their home, at the University of Manitoba/Banntyne Campus, or other community locations acceptable/consented by the participant).
Study: NCT05505825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK104 IV infusion；Chiauranib oral
Description: AK104 IV infusion once every 3 weeks；Chiauranib once a day oral
Study: NCT06113913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Weekly administration of subcutaneous infliximab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Bi-weekly administration of subcutaneous infliximab.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: Optimized dosing schedule of intravenous infliximab.
Study: NCT06062550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Different doses of esketamine in the esketamine-dexmedetomidine combination as a supplement to sufentanil for postoperative intravenous analgesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esketamine
Description: Different doses of esketamine in the esketamine-dexmedetomidine combination as a supplement to sufentanil for postoperative intravenous analgesia.
Study: NCT06187337

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Maxillary expansion device
Description: The maxillary expansion device is a orthodontic appliance that is used to expand the maxilla in children.
Study: NCT05927389

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adapted Physical Activity program
Description: The Adaptated Physical Activity program consists of a Personalized Training Program adapted to each patient's condition and capacities
Study: NCT04923412

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary branch of vagus nerve preserved
Description: During the mediastinal lymph node dissection using minimally invasive surgery, efforts to preserve the pulmonary branch of vagus nerve is made.
Study: NCT06435572

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Suction
Description: Each patient will be evaluated as both the experimental and control group. In the study, open suction applied to the patient will be evaluated as control, and closed suction will be considered as the experimental group. The first suction of the same patient during the day will be done as open suction, and the second suction will be done as closed suction.
Study: NCT04879134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apomorphine Injectable Solution
Description: Patients will receive the treatment while they are in an OFF period, without the effect of any antiparkinsonian medication. For this study, the initial dose of apomorphine or placebo will be 2 mg. We selected an initial standardized dose based on the pharmacological characteristics of apomorphine. Assessments will be completed 30 and 60 minutes after the initial dose. At 60 minutes from the first dose, a 3 mg dose will be administered, and again, assessments will be completed after 30 and 60 minutes. The total given dosage will be 5 mg. Blood pressure and pulse will be checked every 20 minutes after injections.~Other Names:~Movapo
Study: NCT06062550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Different doses of esketamine in the esketamine-dexmedetomidine combination as a supplement to sufentanil for postoperative intravenous analgesia.
Study: NCT06122155

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (Anodal)
Description: 20-minutes, 2 mA anodal tDCS delivering through two 5 cm x 7 cm electrodes
Study: NCT04879134

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% saline placebo injection~Other Names:~• Saline
Study: NCT06122155

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (Anodal)
Description: 20-minutes, 2 mA anodal tDCS delivering through two 5 cm x 7 cm electrodes

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation (Sham)
Description: 20-minutes, 0 mA anodal tDCS delivering through two 5 cm x 7 cm electrodes
Study: NCT05752552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DO-2
Description: Deuterated MET kinase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DO-2
Description: Deuterated MET kinase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DO-2
Description: Deuterated MET kinase inhibitor
Study: NCT06124300

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Female Hormone Balance Supplement
Description: The product contains: Myo-Inositol D-Chiro Inositol Folic Acid Vitamin D Vitamin B12
Study: NCT06517563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VMX-C001
Description: VMX-C001 is human factor X engineered to be insensitive to factor Xa DOACs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VMX-C001
Description: VMX-C001 is human factor X engineered to be insensitive to factor Xa DOACs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: FXa Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UFH
Description: Unfractionated Heparin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: Low Molecular Weight Heparin
Study: NCT04855864

Intervention type: OTHER
Group type: OTHER
Intervention: Follow-up of BCR TKA
Description: Pre- and postoperative follow-up of patients treated with the BCR design by measuring PROMs, and clinical- and radiographic evaluation

Intervention type: OTHER
Group type: OTHER
Intervention: Follow-up of BCS TKA
Description: Pre- and postoperative follow-up of patients treated with the BCS design by measuring PROMs, and clinical- and radiographic evaluation

Intervention type: OTHER
Group type: OTHER
Intervention: Follow-up of PS TKA
Description: Pre- and postoperative follow-up of patients treated with the PS design by measuring PROMs, and clinical- and radiographic evaluation
Study: NCT06135402

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment with Monalisa Glide Laser
Description: 3 fractional laser treatment-sessions with Monalisa Glide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment with Clobetasol
Description: Application of Clobetasol twice per week
Study: NCT05496049

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Triburter
Description: Patients will have to repeat 50 ventilations (start with 20 repetitions in the first week, 30 in the second, 40 in the four week, and 50 in the last week) five days per day for four weeks. And they have to fill a calendar to ensurance the intervention.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Incentive spirometry
Description: They will repeat 10 ventilations per 5 five times a day. Both interventions will be performed for 4 weeks. They have to fill a calendar to ensurance the intervention.